Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Myriad Genetics Community
NasdaqGS:MYGN Community
1
Narratives
written by author
0
Comments
on narratives written by author
1
Fair Values set
on narratives written by author
Create a narrative
Myriad Genetics
Popular
Undervalued
Overvalued
Community Investing Ideas
Myriad Genetics
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
PATHOMIQ AI Partnership Will Expand Oncology And Women's Health
Key Takeaways Strategic partnerships and investments in AI and women's health aim to enhance oncology offerings and capture larger market shares, driving revenue growth. Expansion and innovation in testing and R&D, despite challenges, support future market opportunities and improved financial performance.
View narrative
US$15.82
FV
73.0% undervalued
intrinsic discount
5.91%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
7 days ago
author updated this narrative
Your Valuation for
MYGN
MYGN
Myriad Genetics
Your Fair Value
US$
Current Price
US$4.27
87.6% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-235m
1b
2015
2018
2021
2024
2025
2027
2030
Revenue US$1.1b
Earnings US$217.8m
Advanced
Set Fair Value